

校编码：10384

分类号\_\_\_\_\_密级\_\_\_\_\_

学号：21720090153555

UDC\_\_\_\_\_

厦门大学

博士 学位 论文

视黄酸受体  $\gamma$

在胆管癌发生发展中的作用及其机理

The Role and Mechanism of RAR $\gamma$

in the Development of Cholangiocarcinoma

沈东炎

指导教师姓名： 陈清西 教授

专业名称： 生物化学与分子生物学

论文提交日期： 2012 年 4 月 26 日

论文答辩时间： 2012 年 6 月 1 日

学位授予日期： 2012 年 月 日

答辩委员会主席： 黄河清 教授

评 阅 人： \_\_\_\_\_

2012 年 6 月

## 厦门大学学位论文原创性声明

本人呈交的学位论文是本人在导师指导下，独立完成的研究成果。本人在论文写作中参考其他个人或集体已经发表的研究成果，均在文中以适当方式明确标明，并符合法律规范和《厦门大学研究生学术活动规范（试行）》。

另外，该学位论文为( )课题(组)的研究成果，获得( )课题(组)经费或实验室的资助，在( )实验室完成。(请在以上括号内填写课题或课题组负责人或实验室名称，未有此项声明内容的，可以不作特别声明。)

声明人(签名):

年 月 日

# 厦门大学学位论文著作权使用声明

本人同意厦门大学根据《中华人民共和国学位条例暂行实施办法》等规定保留和使用此学位论文，并向主管部门或其指定机构送交学位论文（包括纸质版和电子版），允许学位论文进入厦门大学图书馆及其数据库被查阅、借阅。本人同意厦门大学将学位论文加入全国博士、硕士学位论文共建单位数据库进行检索，将学位论文的标题和摘要汇编出版，采用影印、缩印或者其它方式合理复制学位论文。

本学位论文属于：

- ( ) 1. 经厦门大学保密委员会审查核定的保密学位论文，于 年 月 日解密，解密后适用上述授权。  
( ) 2. 不保密，适用上述授权。

(请在以上相应括号内打“√”或填上相应内容。保密学位论文应是已经厦门大学保密委员会审定过的学位论文，未经厦门大学保密委员会审定的学位论文均为公开学位论文。此声明栏不填写的，默认为公开学位论文，均适用上述授权。)

声明人(签名)：

年 月 日

### 缩略语表

英文缩写	英文全称	中文全称
MTT	methyl thiazolyltetrazolium	噻唑蓝
PBS	phosphate buffered saline	磷酸盐缓冲液
DMSO	dimethyl Sulfoxide	二甲亚砜
AO	acridine orange	吖啶橙
EB	ethidium bromide	溴乙锭
PI	propidium iodide	碘化丙啶
FCM	flow cytometry	流式细胞术
FITC	fluorescein isothiacyanate	异硫氰酸荧光素
CDK	cyclin-dependent kinase	细胞周期素依赖激酶
RAR $\gamma$	retinoic acid receptor $\gamma$	视黄酸受体 $\gamma$
MDR	multidrug resistance	多药耐药
CCA	cholangiocarcinoma	胆管癌
ICCA	interhepatic cholangiocarcinoma	肝内胆管癌
ECCA	extrahepatic cholangiocarcinoma	肝外胆管癌
CDDP	cis-diamminodichloroplatinum	顺铂
5-FU	5-fluorouracil	5-氟尿嘧啶
TAM	tamoxifen	三苯氧胺
VCR	vincristine	长春新碱
MMC	mitomycin C	丝裂霉素C
MMP-9	matrix metallopeptidase 9	金属蛋白酶-9
P-gp	permeability glycoprotein	P-糖蛋白
PCNA	proliferating cell nuclear antigen	增殖细胞核抗原
CA19-9	carbohydrate antigen 19-9	糖类抗原19-9
CEA	carcinoembryonic antigen	癌胚抗原
MRP	multidrug resistant associated protein	多药耐药相关蛋白
RA	retinoic acid	视黄酸
CDI	coefficient of drug interaction	药物相互作用指数

---

TPA	12-O-Tetradecanoylphorbol-13-Acetate	12-O-十四烷酰佛波醋酸酯-13
IC <sub>50</sub>	50% inhibiting concentration	半抑制浓度
IHC	immunohistochemistry	免疫组织化学
IF	immunofluorescence	免疫荧光学
HRP	horseradish peroxidase	辣根过氧化物酶
ECL	enhanced chemiluminescence	增强型化学发光
PSC	primary sclerotic cholangitis	原发性硬化性胆管炎
LRP	lung resistance related protein	肺耐药相关蛋白
ABCC	ATP-binding cassette superfamily C	三磷酸腺苷结合盒转运体基因
Gal-3	galectin-3	半乳凝素-3
TS	thymidylate synthase	胸腺嘧啶核酸合酶
GST- $\pi$	glutathione S transferase	谷胱甘肽 S 转移酶 $\pi$
BCRP	breast cancer resistance protein	乳腺癌耐药蛋白
RARE	RA responsive element	视黄酸应答元件
NLS	nuclear localization sequence	核定位序列
NES	nuclear export sequence	出核序列

---

## 目 录

<b>中文摘要</b>	1
<b>Abstract</b>	2
<b>第一章 前言</b>	4
<b>1. 胆管癌临床研究概况</b>	4
1.1 胆管癌分类	4
1.2 胆管癌流行病学与危险因素	5
1.3 胆管癌临床诊断	6
1.4 胆管癌临床治疗	7
<b>2. 胆管癌分子生物学研究进展</b>	8
2.1 胆管癌发生发展分子机制	8
2.2 胆管癌转移分子机制	10
2.3 胆管癌耐药性产生机理	11
<b>3. 视黄酸受体研究进展</b>	12
3.1 核受体家族	12
3.2 视黄酸受体家族	13
3.3 RAR $\gamma$ 生物学功能与肿瘤	15
<b>4. 七叶皂苷钠与肿瘤关系的研究进展</b>	18
4.1 七叶皂苷钠功效	18
4.2 七叶皂苷钠抗肿瘤作用	19
<b>5. 本研究的内容和科学意义</b>	21
5.1 研究内容	21
5.2 科学意义	21
<b>第二章 材料与方法</b>	22
<b>1. 实验材料</b>	22
1.1 胆管癌组织标本	22
1.2 细胞株	22
1.3 试剂与配置	22

1.3.1 各类试剂列表.....	22
1.3.2 主要试剂配置.....	27
1.4 主要仪器.....	29
<b>2. 实验方法 .....</b>	<b>30</b>
2.1 细胞培养.....	30
2.2 载体构建与转染.....	30
2.2.1 瞬时干扰片段转染.....	30
2.2.2 病毒转染.....	30
2.3 细胞学染色.....	33
2.3.1 姬姆萨染色.....	33
2.3.2 Hoechst 33258 染色 .....	33
2.3.3 AO/EB 染色.....	34
2.4 流式细胞术.....	34
2.5 MTT 法 .....	34
2.6 实时荧光定量 PCR.....	34
2.7 Western blot 法 .....	34
2.8 免疫组织化学.....	35
2.9 细胞免疫荧光法.....	36
2.10 集落形成实验.....	37
2.11 迁移与侵袭实验.....	37
2.12 酶谱法.....	37
2.13 化学药物联合实验.....	38
2.14 裸鼠皮下移植瘤实验.....	38
2.15 胆管癌细胞耐药模型建立.....	38
2.16 统计分析.....	38
<b>第三章 结果与分析 .....</b>	<b>39</b>
<b>1. RAR<math>\gamma</math> 在胆管癌组织中的表达及其临床意义 .....</b>	<b>39</b>
1.1 RAR $\gamma$ 在胆管癌组织的表达情况.....	39
1.2 RAR $\gamma$ 在胆管癌中表达的临床意义.....	43

<b>2. RAR<math>\gamma</math> 促进胆管癌细胞的生长与成瘤</b>	45
2.1 RAR $\gamma$ 表达下调抑制胆管癌细胞体外生长	45
2.2 RAR $\gamma$ 表达下调抑制胆管癌细胞集落形成	48
2.3 RAR $\gamma$ 表达下调抑制胆管癌细胞裸鼠皮下瘤形成	49
<b>3. RAR<math>\gamma</math> 促进胆管癌细胞的迁移与侵袭</b>	50
<b>4. RAR<math>\gamma</math> 与胆管癌细胞耐药性的关系</b>	52
4.1 RAR $\gamma$ 表达下调提高胆管癌细胞的药物敏感性	52
4.2 RAR $\gamma$ 表达下调逆转胆管癌细胞的耐药性	53
<b>5. RAR<math>\gamma</math> 参与胆管癌发生发展的分子机制研究</b>	56
5.1 RAR $\gamma$ 参与调控胆管癌细胞周期	56
5.2 RAR $\gamma$ 调控生长与成瘤、迁移与侵袭及耐药性相关分子的表达	57
5.3 RAR $\gamma$ 调控 PI3K/Akt 和 NF- $\kappa$ B 信号通路	59
<b>6. 七叶皂苷钠抗胆管癌作用与 RAR<math>\gamma</math> 的关系研究</b>	64
6.1 七叶皂苷钠具有显著的抗胆管癌作用	64
6.2 七叶皂苷钠诱导胆管癌细胞周期阻滞与细胞凋亡	65
6.3 七叶皂苷钠在抗胆管癌治疗上的应用	67
6.4 七叶皂苷钠与 RAR $\gamma$ 蛋白的关系	71
<b>第四章 讨论</b>	74
1. RAR $\gamma$ 在胆管癌组织高表达具有重要的临床意义	74
2. RAR $\gamma$ 在胆管癌细胞中高表达促进胆管癌细胞生长与成瘤	75
3. RAR $\gamma$ 通过提高 MMP-9 活性促进胆管癌细胞迁移与侵袭	77
4. RAR $\gamma$ 通过上调 P-gp 表达促进胆管癌细胞产生耐药性	78
5. RAR $\gamma$ 胞浆转移调控 PI3K/Akt 和 NF- $\kappa$ B 信号通路	79
6. 七叶皂苷钠抑制 RAR $\gamma$ 胞浆转移	81
<b>全文小结</b>	83
<b>创新点</b>	84
<b>展望</b>	85
<b>参考文献</b>	86

博士期间参与发表的文章 .....	101
致谢 .....	102

厦门大学博硕士论文摘要库

## Table of Contents

<b>Abstract in Chinese</b> .....	1
<b>Abstract in English</b> .....	2
<b>Chapter One    Introduction</b> .....	4
1.    General clinical research introduction of cholangiocarcinoma .....	4
1.1    Classification of cholangiocarcinoma .....	4
1.2    Epidemiology and risk factors of cholangiocarcinoma .....	5
1.3    Clinical diagnosis of cholangiocarcinoma .....	6
1.4    Clinical treatment of cholangiocarcinoma .....	7
2.    Advances in molecular biology of cholangiocarcinoma .....	8
2.1    The molecular mechanism of cholangiocarcinoma development .....	8
2.2    Molecular mechanisms of cholangiocarcinoma metastasis .....	10
2.3    Drug resistance mechanism of cholangiocarcinoma .....	11
3.    Retinoic acid receptor research progress .....	12
3.1    Nuclear receptor family .....	12
3.2    Retinoic acid receptor family .....	13
3.3    RAR $\gamma$ biological function and tumor .....	15
4.    Association of tumor and sodium aescine .....	18
4.1    Sodium aescine efficiency .....	18
4.2    Antitumor effect of sodium aescine .....	19
5.    Content and meaning of the study .....	21
5.1    Research content .....	21
5.2    Science meaning .....	21
<b>Chapter Two    Materials and methods</b> .....	22
1.    Materials .....	22
1.1    Cholangiocarcinoma tissues .....	22
1.2    Cell lines .....	22
1.3    Reagent and configuration .....	22

1.3.1 List of all types of reagents.....	22
1.3.2 The main reagent configuration .....	27
1.4 Primary instrument.....	29
<b>2. Methods.....</b>	<b>30</b>
2.1 Cell culture.....	30
2.2 Vector construction and transfection.....	30
2.2.1 Instantaneous interference fragment transfection .....	30
2.2.2 Virus transfection .....	30
2.3 Cytology stain .....	33
2.3.1 Giemsa dyeing .....	33
2.3.2 Hoechst 33258 dyeing.....	33
2.3.3 AO/EB dyeing.....	34
2.4 Flow cytometry .....	34
2.5 MTT .....	34
2.6 Real time PCR.....	34
2.7 Western blot .....	34
2.8 Immunohistochemistry .....	35
2.9 Immunofluorescence .....	36
2.10 Colony forming.....	37
2.11 Migration and invasion .....	37
2.12 Zymography .....	37
2.13 Drug combination .....	38
2.14 Transplanted subcutaneously in nude mice .....	38
2.15 Establish of CCA MDR cell model.....	38
2.16 Statistical analysis .....	38
<b>Chapter Three Results and analysis.....</b>	<b>39</b>
<b>1. Clinic significance and expression of RAR<math>\gamma</math> in cholangiocarcinoma .....</b>	<b>39</b>
1.1 Expression of RAR $\gamma$ in CCA tissues.....	39
1.2 Clinic significance of RAR $\gamma$ in CCA.....	43

<b>2. RAR<math>\gamma</math> promoting Growth and tumor of CCA cells.....</b>	45
2.1 Inhibition of CCA cells growth in vitro after downregulationof RAR $\gamma$ .....	45
2.2 Inhibition of CCA cells clony forming after downregulationof RAR $\gamma$ .....	48
2.3 Inhibition of CCA cells growth in vivo after downregulationof RAR $\gamma$ .....	49
<b>3. RAR<math>\gamma</math> promoting migration and invasion of CCA cells .....</b>	50
<b>4. Association of RAR<math>\gamma</math> and drug resistance of CCA cells .....</b>	52
4.1 Improve CCA cell drug sensitivity after downregulationof RAR $\gamma$ .....	52
4.2 Reversal of CCA cell drug resistance after downregulationof RAR $\gamma$ .....	53
<b>5. Research on molecular mechanism of RAR<math>\gamma</math> in the development of CCA..</b>	56
5.1 Cell cycle regulation of RAR $\gamma$ in CCA.....	56
5.2 RAR $\gamma$ regulation in proliferation, metastasis, and resisitance associated genes.	57
5.3 Regulation of RAR $\gamma$ in PI3K/Akt and NF- $\kappa$ B signal passways .....	59
<b>6. Relationship of sodium aescine and RAR<math>\gamma</math> in anti-CCA.....</b>	64
6.1 Marked effect of sodium aescine in anti-CCA .....	64
6.2 Induced CCA cell cycle arrested and cell apoptosis by sodium aescine .....	65
6.3 Application of sodium aescine in antitumor of CCA.....	67
6.4 Association of sodium aescine and RAR $\gamma$ .....	71
<b>Chapter Four Discussion .....</b>	74
<b>1. Overexpression of RAR<math>\gamma</math> in CCA has important clinic significance .....</b>	74
<b>2. Overexpression of RAR<math>\gamma</math> promoting proliferation of CCA cells .....</b>	75
<b>3. RAR<math>\gamma</math> promoting metastasis of CCA cells by upregulating MMP-9.....</b>	77
<b>4. RAR<math>\gamma</math> promoting drug resistance of CCA cells by upregulating P-gp.....</b>	78
<b>5. Regulation of RAR<math>\gamma</math> in PI3K/Akt and NF-<math>\kappa</math>B signal passways .....</b>	79
<b>6. Inhibition of RAR<math>\gamma</math> cytoplasmic translocation of sodium aescine .....</b>	81
<b>Conclusions .....</b>	83
<b>Innovation points .....</b>	84
<b>Lookings .....</b>	85
<b>References .....</b>	86

<b>Publications</b>	101
<b>Acknowledgements</b>	102

厦门大学博硕士论文摘要库

## 中文摘要

胆管癌是一种起源于胆管上皮细胞的肝胆系统恶性肿瘤。由于解剖位置特殊、临床症状隐匿、早期诊断困难、易以多种方式发生转移、术后容易复发以及放化疗不敏感，胆管癌预后较差。因此，深入研究胆管癌发生发展、侵袭转移以及耐药性产生的分子机制具有重要的意义。视黄酸受体与肿瘤的关系一直是研究的关注点，然而，RAR $\gamma$ 参与肿瘤发生发展的作用及其分子机制尚不清楚。本论文以胆管癌为研究对象，以 RAR $\gamma$ 为切入点，研究 RAR $\gamma$ 在胆管癌发生发展中的作用及其分子机制，并寻找新的有效的抗胆管癌效应物。

本论文研究发现，RAR $\gamma$ 在胆管癌组织中基因和蛋白水平表达明显高于配对癌旁组织，以及胆管炎和正常胆管组织，且 RAR $\gamma$ 异常表达于胞浆。RAR $\gamma$ 高表达与胆管癌病理分级的低分化、淋巴结转移、血清 CA19-9 高值以及预后差密切相关。采用基因转染技术下调胆管癌细胞 RAR $\gamma$ 的表达，结果发现：RAR $\gamma$ 表达下调导致胆管癌细胞 QBC939、SK-ChA-1 和 MZ-ChA-1 生长明显缓慢，体外细胞集落形成和体内裸鼠皮下异种成瘤受到抑制，这与其表达下调介导 p21 表达上调而诱导细胞周期阻滞以及 PCNA 表达下调有关；RAR $\gamma$ 表达下调导致 MMP-9 表达与活性下降，从而抑制胆管癌细胞的迁移与侵袭；RAR $\gamma$ 表达下调介导胆管癌细胞耐药性相关蛋白 P-gp 表达下调从而提高胆管癌细胞对 5-氟尿嘧啶、顺铂、长春新碱和丝裂霉素 C 的敏感性及逆转本实验构建的胆管癌细胞耐药模型 QBC939/5-FU 的耐药性。进一步研究发现，RAR $\gamma$ 表达下调后降低 AKT 和 I $\kappa$ B $\alpha$ 的磷酸化水平，PI3K/Akt 和 NF- $\kappa$ B 信号通路抑制剂可以影响 p21、PCNA、MMP-9 和 P-gp 的表达。由此表明，RAR $\gamma$ 是通过胞浆转移调控 PI3K/AKT/NF- $\kappa$ B 信号通路从而介导与胆管癌发生发展密切相关的 p21、PCNA、MMP-9 和 P-gp 等基因表达改变，最终实现其癌基因作用。

本文在筛选抗胆管癌效应物研究中发现，七叶皂苷钠通过诱导胆管癌细胞周期抑制和细胞凋亡发挥其抗胆管癌作用，其药效明显高于其他临床胆管癌化疗药物；七叶皂苷钠还可逆转胆管癌细胞耐药性，提高其他抗肿瘤药物的抗癌活性。七叶皂苷钠这种生物学效应是通过抑制 RAR $\gamma$ 在胆管癌细胞的胞浆转移，从而达到抑制 PI3K/Akt/NF- $\kappa$ B 信号通路的活性而实现的。

**关键词：**胆管癌；RAR $\gamma$ ；七叶皂苷钠

## Abstract

Cholangiocarcinomas (CCA) are rare malignant tumors arising from the biliary tract. Because of special anatomical position, conceal anatomical position, difficulty in early diagnosis, metastasis by a variety of ways, easy to relapse after surgery, and insensitivity to insensitivity, its prognosis is poor. Therefore, it is important to intensively study the mechanisms of the development, metastasis, and the multidrug resistance of CCA. The relationship of retinoic acid receptors and tumor is always the research focus. However, the roles and mechanism of RAR $\gamma$  in the development of CCA were unclear. In this study, as the object of study in CCA and the breakthrough point with RAR $\gamma$ , we study the the roles and mechanism of RAR $\gamma$  in the development of CCA, and search for new effective drug to CCA.

In the current study, we found that the expression of RAR $\gamma$  mRNA and protein were abnormal in cell cytoplasm and elevated in CCA tissues compared to paired noncancerous tissues, cholangitis tissues, and normal bile duct tissues. Its overexpression was closely associated with pathology of low differentiation, lymphatic metastasis, serum CA19-9 high value and poor prognosis. It was found that after downregulation of RAR $\gamma$  in CCA cells by gene transfer techniques: Inhibiton of cells growth in vitro, cells clone formation, and xenograft tumor in nude mice in vivo, which were associated with cell cycle arrested by upregulation of p21 and downregulation of PCNA. Inhibiton of cells migration and invasion by decreased the expression of MMP-9 and activity. Enhancement of drug susceptibility of CCA cells to 5-FU, CDDP, VCR, and MMC, reversion of QBC939/5-FU multidrug resistance, which was associated with the downregulation of P-gp. Furthermore, the phosphorylation level of AKT and I $\kappa$ B $\alpha$  were decreased after downregulation of RAR $\gamma$ , and the inhibitor of PI3K/Akt or NF- $\kappa$ B signal passway could change the expression of p21, PCNA, MMP-9, and P-gp. It was showed that RAR $\gamma$  exerted its oncogene activation by mediating the expression of p21, PCNA, MMP-9, and P-gp in way of regulating the PI3K/Akt/NF- $\kappa$ B signal passway.

In the screening of CCA effectors, we found that  $\beta$ -escin inhibited the

proliferation of CCA cells by inducing cell cycle arrested and cell apoptosis, and the antiproliferative effect was stronger than all the other chemotherapeutic agents of the same concentration. Furthermore,  $\beta$ -escin not only reversed the multidrug resistance of QBC939/5-FU, but also enhanced the drug susceptibility of CCA cells. The functions of  $\beta$ -escin were exhibited by regulation of PI3K/Akt/NF- $\kappa$ B signal passway through inhibiting RAR $\gamma$  cytoplasmic translocation.

**Keywords:** cholangiocarcinoma; RAR $\gamma$ ;  $\beta$ -escin.

Degree papers are in the "[Xiamen University Electronic Theses and Dissertations Database](#)". Full texts are available in the following ways:

1. If your library is a CALIS member libraries, please log on <http://etd.calis.edu.cn/> and submit requests online, or consult the interlibrary loan department in your library.
2. For users of non-CALIS member libraries, please mail to [etd@xmu.edu.cn](mailto:etd@xmu.edu.cn) for delivery details.

厦门大学博硕士论文摘要库